Editor's Note: the "Trending USA Stocks" column tracks the day's top bullish stocks in the USA market, aiding investors in promptly identifying opportunities for potential gains.

10/09/2024 Eastern Time in the USA The Dow Jones Industrial Average dropped by 0.23%, closing at 40736.96 points; the Nasdaq Composite rose by 0.84%, closing at 17025.88 points; the S&P 500 Index rose by 0.45%, closing at 5495.52 points. Sahm has compiled the Top 10 Daily Stock Price Gainers in the USA market.

iLearningEngines Holdings, Inc. - Class A Common Stock: Overnight gain 115.1%, AI firm counters short-seller claims, boosting investor confidence despite previous declines.

Company profile missing.

iLearningEngines Holdings, Inc. - Class A Common Stock (AILE) experienced a significant stock price surge as the company proactively addressed short-seller allegations. The formation of a special committee comprising independent directors demonstrates AILE's commitment to addressing investor concerns. CEO Harish Chidambaran's public emphasis on the company's long-term performance and financial stability has helped bolster market confidence. As a leader in enterprise AI-driven learning and work automation, AILE's prominent position in the current AI boom has attracted investor attention. Despite an 85.1% year-to-date decline, the recent 115.1% rally reflects a reversal in market sentiment, with investors perceiving the stock as oversold. This rebound underscores the market's renewed interest in AILE's potential within the rapidly evolving AI sector.

FibroBiologics (Direct Listing): Overnight gain 49.6%

FibroBiologics, an emerging biotechnology firm headquartered in Houston, Texas, is making strides in the field of cell therapy. The company specializes in developing innovative treatments for chronic diseases using fibroblast-based therapies. The firm's research pipeline focuses on several key areas, including degenerative disc disease, multiple sclerosis, cancer, and wound healing. FibroBiologics is actively advancing its preclinical studies and FDA clinical trials, aiming to provide novel therapeutic solutions for a range of medical conditions. As a pioneer in fibroblast-based cell therapies, FibroBiologics is positioned at the forefront of regenerative medicine. The company's approach leverages the potential of fibroblasts to address unmet medical needs and potentially revolutionize treatment paradigms for chronic diseases. Investors and industry observers are closely watching FibroBiologics' progress as it navigates the complex landscape of biotechnology development and regulatory approval processes. The success of its ongoing research and clinical trials could have significant implications for both patients and the broader healthcare sector.

FibroBiologics (Direct Listing)(FBLG) experienced a significant surge in its stock price, driven by a positive analyst rating and an ambitious price target. EF Hutton analyst Jason Kolbert initiated coverage on FibroBiologics with a "Buy" rating and set a $16 price target, instilling confidence among investors and propelling the stock up by 49.6%. Despite this rally, FBLG remains down 51.4% year-to-date, suggesting the recent uptick may be a correction to previous overselling. As an early-stage cell therapy company, FibroBiologics' innovative potential and diversified research pipeline have attracted investor attention, further supporting the stock's upward momentum. This development underscores the impact of analyst sentiment on emerging biotech firms and highlights the volatile nature of the sector.

Viridian Therapeutics Inc Ordinary Shares: Overnight gain 32.1%, Positive clinical trial results for thyroid eye disease drug boost investor confidence

Viridian Therapeutics, Inc. (NASDAQ: VRDN) is a clinical-stage biopharmaceutical company focused on developing innovative therapies for severe and rare diseases. The company strategically targets disease areas with limited competition, aiming to create best-in-class, differentiated therapeutics that offer improved efficacy, safety, and patient convenience. The firm's pipeline is currently anchored by three candidate products for the treatment of Thyroid Eye Disease (TED), a rare autoimmune disorder. Leading the portfolio is VRDN-001, the company's most advanced program, which is a differentiated humanized monoclonal antibody targeting the insulin-like growth factor-1 receptor (IGF-1R). By concentrating on underserved markets and leveraging cutting-edge biotechnology, Viridian Therapeutics is positioning itself as a potential disruptor in the rare disease therapeutics space. The company's approach aligns with the growing trend in the pharmaceutical industry towards precision medicine and targeted therapies for orphan diseases. Investors and industry observers will be closely monitoring the progress of VRDN-001 and the company's other pipeline candidates as they advance through clinical trials, which could potentially drive significant value creation for the company in the coming years.

Viridian Therapeutics Inc Ordinary Shares (VRDN) experienced a significant stock price surge following the announcement of positive preliminary results from its THRIVE Phase III clinical trial for veligrotug (VRDN-001) in Thyroid Eye Disease (TED) patients. The trial met its primary endpoint, demonstrating a 70% proptosis response rate, substantially outperforming the placebo group's 5%. Multiple secondary endpoints were also achieved, including complete resolution of diplopia. Safety data revealed mostly mild adverse events with no serious incidents reported. These encouraging results bolstered investor confidence, driving the stock up 32.1%. Viridian plans to submit a Biologics License Application in the second half of 2025, providing a clear roadmap for future development. This milestone marks a significant advancement in TED treatment and strengthens VRDN's position in the biotechnology sector.

The Top 10 Daily Gainers in the USA market are listed as follows: